LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Список акций・Vivani Medical

Vivani Medical

Закрыт

1.52 4.83

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.3900000000000001

Макс.

1.52

Ключевые показатели
By Trading Economics
Сотрудники	37

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+175.86% upside

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-15M 89M
Предыдущая цена открытия	-3.31
Предыдущая цена закрытия	1.52

Vivani Medical График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

9 дек. 2025 г., 22:13 UTC

Отчет

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 дек. 2025 г., 21:40 UTC

Отчет

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 дек. 2025 г., 18:51 UTC

Приобретения, слияния, поглощения

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 дек. 2025 г., 16:57 UTC

Главные движущие силы рынка

Clear Secure Rises on Medicare Identity Verification Contract

9 дек. 2025 г., 23:46 UTC

Обсуждения рынка

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 дек. 2025 г., 23:46 UTC

Приобретения, слияния, поглощения

Legend Holdings Stake in Lenovo Now at 32.34%

9 дек. 2025 г., 23:45 UTC

Приобретения, слияния, поглощения

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 дек. 2025 г., 23:44 UTC

Приобретения, слияния, поглощения

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 дек. 2025 г., 23:43 UTC

Приобретения, слияния, поглощения

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 дек. 2025 г., 23:43 UTC

Приобретения, слияния, поглощения

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 дек. 2025 г., 23:35 UTC

Обсуждения рынка

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 дек. 2025 г., 22:42 UTC

Отчет

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Tech, Media & Telecom Roundup: Market Talk

9 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

9 дек. 2025 г., 21:48 UTC

Обсуждения рынка

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 дек. 2025 г., 21:36 UTC

Отчет

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 дек. 2025 г., 20:28 UTC

Обсуждения рынка

Oil Futures Decline for Second Straight Session -- Market Talk

9 дек. 2025 г., 20:27 UTC

Приобретения, слияния, поглощения

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 дек. 2025 г., 20:27 UTC

Приобретения, слияния, поглощения

Teck Reports Voting Results From Special Meeting of Hldrs

9 дек. 2025 г., 20:26 UTC

Обсуждения рынка

Приобретения, слияния, поглощения

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 дек. 2025 г., 20:21 UTC

Обсуждения рынка

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 дек. 2025 г., 19:52 UTC

Отчет

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 дек. 2025 г., 19:17 UTC

Отчет

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 дек. 2025 г., 17:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

9 дек. 2025 г., 17:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

9 дек. 2025 г., 17:11 UTC

Отчет

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Vivani Medical Прогноз

Целевая цена

By TipRanks

175.86% рост

Прогноз на 12 месяцев

Средняя 4 USD 175.86%

Максимум 4 USD

Минимум 4 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Vivani Medical на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

Покупка

Удержание

Продажа

Основано на мнении 2 аналитиков, присваивавших рейтинги акциям Vivani Medical – Данные за последние 3 месяца.

Финансовые показатели

О компании Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.